A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

NCT06876662 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

279

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma

Interventions

DRUG: Pirtobrutinib

Sponsor

Eli Lilly and Company